Epidemiology and disease burden of tuberous sclerosis complex in France: A population‐based study based on national health insurance data

Autor: Francis Fagnani, Caroline Laurendeau, Marie deZelicourt, Jade Marshall

Publikováno v: Epilepsia Open, Vol 7, Iss 4, Pp 633-644 (2022)

Abstract Objective Tuberous sclerosis complex (TSC) is a rare multisystem disorder, often associated with epilepsy. This retrospective study aimed to identify patients with TSC, including those with epilepsy, from a French healthcare claims database,

Externí odkaz: https://doaj.org/article/eea71e6170ba4a46ba6876f42981e9ba

Early non-response to certolizumab pegol in rheumatoid arthritis predicts failure to achieve low disease activity at 1 year: data from a prospective observational study

Autor: Bernard Combe, Rene-Marc Flipo, Alain Saraux, Francis Fagnani, Jacques Massol, Gabrielle Cukierman, Jean-Michel Joubert, Philippe Huot-Marchand

Publikováno v: RMD Open, Vol 6, Iss 1 (2020)

Objective To evaluate the performance of clinical criteria for predicting late treatment failure in patients with early non-response to certolizumab pegol (CZP).Methods A protocol-specified analysis of interim data from ECLAIR, a 3-year longitudinal,

Externí odkaz: https://doaj.org/article/a7c0fd1c17fd440db3df7951cfa3bfb5

Patterns of Use and Clinical Outcomes with Long-Acting Somatostatin Analogues for Neuroendocrine Tumors: A Nationwide French Retrospective Cohort Study in the Real-Life Setting

Autor: Brooke Harrow, Francis Fagnani, Camille Nevoret, Xuan-Mai Truong-Thanh, Marie de Zélicourt, Louis de Mestier

Publikováno v: Advances in Therapy. 39:1754-1771

Long-acting somatostatin analogues such as lanreotide autogel (LAN) and octreotide long-acting release (OCT) are recommended as first-line treatment for patients with neuroendocrine tumors (NETs). However, only few real-world studies have compared th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28df52c328f3ca947be05c40d4c72199
https://doi.org/10.1007/s12325-022-02060-1

Three-year clinical outcomes in patients with rheumatoid arthritis treated with certolizumab pegol: results from the observational ECLAIR study

Autor: Alain Saraux, Bernard Combe, Francis Fagnani, Gabrielle Cukierman, Isabelle Bru, Jean-Michel Joubert, Jan-Christof Schuller, Jacques Massol, Rene-Marc Flipo

Publikováno v: Clinical and experimental rheumatology
Clinical and experimental rheumatology, Clinical and Experimental Rheumatology Sas, 2021, 39 (4), pp.781-789

International audience; Objectives: To describe the long-term effectiveness and safety of certolizumab pegol in patients with moderate-to-severe rheumatoid arthritis (RA) in a real-world setting in France.Methods: ECLAIR was a 3-year longitudinal, pr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f9f43619c59d8b8175ba814c2a7fc280
https://hal.umontpellier.fr/hal-03340763

Burden of severe spondyloarthritis in France: A nationwide assessment of prevalence, associated comorbidities and cost

Autor: Caroline Laurendeau, Julie Gourmelen, G. Cukierman, Maxime Breban, Jean-Michel Joubert, Pascal Claudepierre, Thibault de Chalus, Francis Fagnani

Publikováno v: Joint Bone Spine
Joint Bone Spine, Elsevier Masson, 2019, 86, pp.69-75. ⟨10.1016/j.jbspin.2018.04.003⟩

Objectives To estimate the number of patients with severe spondyloarthritis (SpA) in France, describe their comorbidities and document and value their healthcare resource consumption. Methods Data were retrieved from an insurance claims database cove

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c2b15a9ca8b554c1a81118ecae13d23
https://doi.org/10.1016/j.jbspin.2018.04.003